Effect of dopaminergic treatment on digital sensor features in Phase II PASADENA Part 1 in early Parkinson’s disease
Objective: To characterize the sensitivity of smartphone and -watch sensor features to levodopa and dopamine agonist (DA-Tx) treatment. Background: Digital health technology tools (DHTTs) enable…Determining the content of a clinician-rated tool for freezing of gait severity
Objective: This study aimed to determine clinician’s ratings of the most important triggering circumstances to be examined and aspects of freezing of gait (FOG) to…Diagnostic accuracy in an incidence cohort of Parkinson’s disease
Objective: To determine the accuracy of clinical diagnosis and research diagnostic criteria in a population-representative cohort of Parkinson's disease (PD) against a neuropathological gold standard…Reproductive factors and risk of Parkinson’s disease in women: preliminary results from the French prospective cohort E3N.
Objective: Objective: To evaluate whether reproductive factors and use of exogenous hormones are associated with the risk of Parkinson’s disease (PD) in women. Background: Background:…Impact of extended quarantine during the COVID-19 pandemic on Parkinson’s disease (PD) patients.
Objective: To determine the impact of extended quarantine during the COVID-19 pandemic in PD patients. Background: Due to the Covid-19 pandemic, various types of social…Terminal Choking in Parkinson’s Disease
Objective: To establish whether choking is a frequent cause of death in Parkinson’s Disease (PD), if this is a feared consequence of PD in patients/caregivers…Efficacy of opicapone according to different levodopa daily intakes in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuation according to different levodopa daily intakes. Background: OPC proved…Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects
Objective: To evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of ABBV-0805 following administration of single ascending doses of ABBV-0805, administered as intravenous (IV) infusions…Decreased expression of trace amines receptors on lymphocytes in Parkinson’s disease
Objective: To determine the expression of TAAR1 and TAAR2 mRNA in leukocytes of patients with Parkinson's disease, depending on the stage of the disease and…Potential drug-drug interactions in hospitalized patients with Parkinson’s disease from tertiary center in Serbia
Objective: The aim of this study was to identify predictors of potential drug-drug interactions in patients suffering from Parkinson’s disease.The aim of this study was…
- « Previous Page
- 1
- …
- 430
- 431
- 432
- 433
- 434
- …
- 436
- Next Page »